Abciximab therapy in percutaneous intervention : Economic issues in the United States : Use of GP IIb/IIIa inhibitors in coronary syndromes : State of the Art.
Whether abciximab therapy should be the standard of care during percutaneous intervention in the United States depends on its efficacy, safety, and economics.
In view of the EPIC, CAPTURE, and EPILOG data, few question the superior efficacy and relative safety of abciximab compared with conventional high-dose heparin therapy during percutaneous intervention.
Economic considerations have been the major issue limiting its use.
Review of the economic data demonstrates that the incremental direct medical care cost of abciximab therapy is $290 to $600 per patient treated in the EPIC and EPILOG populations.
In the patients with acute myocardial infarction and unstable angina, abciximab appears to reduce direct medical costs (produce cost savings) at 6 months.
Given abciximab's significant incremental effectiveness, its relatively small incremental cost yielded a highly cost-effective therapy in the EPIC and EPILOG patient populations.
Additional economic issues relate to minimizing bleeding complications, indirect costs, reduced frequency of emergency procedures, and rationalizing provider/payor policies and incentives to produce the optimal individual patient and societal outcomes.
The currently available data concerning the efficacy, safety, and cost provide a compelling argument for embracing abciximab therapy in the treatment of patient subsets where it will be a cost-saving or cost-neutral adjunct to percutaneous coronary intervention. (...)
Mots-clés Pascal : Abciximab, Inhibiteur, Glycoprotéine, Voie percutanée, Traitement instrumental, Etats Unis, Amérique du Nord, Amérique, Coût, Economie santé, Chimiothérapie, Traitement, Cardiopathie coronaire, Inhibiteur thromboagrégation, Appareil circulatoire pathologie, Glycoprotéine IIbIIIa
Mots-clés Pascal anglais : Abciximab, Inhibitor, Glycoproteins, Percutaneous route, Instrumentation therapy, United States, North America, America, Costs, Health economy, Chemotherapy, Treatment, Coronary heart disease, Antiplatelet agent, Cardiovascular disease, Glycoprotein IIbIIIa
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0218384
Code Inist : 002B02G. Création : 11/09/1998.